Publications
Detailed Information
Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Nayoung | - |
dc.contributor.author | Kim, Chung Hyun | - |
dc.contributor.author | Ahn, Dong-Won | - |
dc.contributor.author | Lee, Kyoung Soo | - |
dc.contributor.author | Park, Ji Hyun | - |
dc.contributor.author | Kim, Joo Sung | - |
dc.contributor.author | Song, In Sung | - |
dc.contributor.author | Jung, Hyun Chae | - |
dc.contributor.author | Lee, Mi Kyoung | - |
dc.contributor.author | Cho, Soo-Jeong | - |
dc.date.accessioned | 2012-05-23T08:25:55Z | - |
dc.date.available | 2012-05-23T08:25:55Z | - |
dc.date.issued | 2009-03 | - |
dc.identifier.citation | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY; Vol.24 3; 480-487 | ko_KR |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76350 | - |
dc.description.abstract | Previously, we showed that treatment with celecoxib significantly reduced the number of viable gastric cancer cells, in a dose- and time-dependent manner. However, the specific anti-cancer effects of celecoxib on gastric cancer cells have not been clarified. The present in vitro study was carried out to investigate the mechanism involved in the anti-gastric cancer effects of celecoxib. 3-(4,5-Dimethyl-2 thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay was carried out after treating AGS cells (human gastric cancer cell line, ATCC CRL 1739) with celecoxib or indomethacin, and the effect of prostaglandin E(2) or LY294002 (PI3K inhibitor) was evaluated. Western blot analysis of tAkt (total Akt), pAkt (phosphorylated Akt), pGSK3 beta (phosphorylated glycogen synthase kinase-3 beta), pFKHR (phosphorylated forkhead transcriptional factor), and caspase-9 was carried out at various concentrations (0, 5, 10, 25, or 50 mu mol/L) of celecoxib or indomethacin-treatment for 24 or 48 h in AGS cells. Celecoxib- or LY294002-induced cell death was found to occur in a dose-dependent manner in AGS cells, and these decreases were slightly recovered by the addition of PGE(2) (25 or 50 mu mol/L). The expression of pAkt but not tAkt was lower in the celecoxib treated-AGS cells and the response was dose dependent (P < 0.05). The expression of pGSK3 beta and pFKHR was also significantly decreased in the celecoxib treated-AGS cells. Procaspase 9 (47 kDa) was frequently cleaved into 37, 35 and 17 kDa fragments in the celecoxib-treatment group. However, these changes in cell signal transduction were not observed in the indomethacin treated-AGS cells. The anti-cancer effects of celecoxib on gastric cancer cells might be partly mediated by downregulation of Akt, GSK3 beta, FKHR, and upregulation of caspase-9, in the mitochondrial apoptotic pathway. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL PUBLISHING, INC | ko_KR |
dc.subject | Akt | ko_KR |
dc.subject | gastric cancer | ko_KR |
dc.subject | celecoxib | ko_KR |
dc.subject | apoptosis | ko_KR |
dc.title | Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김나영 | - |
dc.contributor.AlternativeAuthor | 김정현 | - |
dc.contributor.AlternativeAuthor | 안동원 | - |
dc.contributor.AlternativeAuthor | 이경수 | - |
dc.contributor.AlternativeAuthor | 조수정 | - |
dc.contributor.AlternativeAuthor | 박지현 | - |
dc.contributor.AlternativeAuthor | 이미경 | - |
dc.contributor.AlternativeAuthor | 김주성 | - |
dc.contributor.AlternativeAuthor | 정현채 | - |
dc.contributor.AlternativeAuthor | 송인성 | - |
dc.identifier.doi | 10.1111/j.1440-1746.2008.05599.x | - |
dc.citation.journaltitle | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.description.citedreference | Chan AT, 2008, GASTROENTEROLOGY, V134, P21, DOI 10.1053/j.gastro.2007.09.035 | - |
dc.description.citedreference | Lee BL, 2008, CARCINOGENESIS, V29, P44, DOI 10.1093/carcin/bgm232 | - |
dc.description.citedreference | Cho SJ, 2007, DIGEST DIS SCI, V52, P1713, DOI 10.1007/s10620-007-9787-3 | - |
dc.description.citedreference | Murakami D, 2007, GASTRIC CANCER, V10, P45, DOI 10.1007/s10120-006-0410-7 | - |
dc.description.citedreference | Rojo F, 2006, J CLIN ONCOL, V24, P4309, DOI 10.1200/JCO.2005.04.2424 | - |
dc.description.citedreference | *KOR MIN HLTH WELF, 2006, 3 NAT HLTH NUTR EX S | - |
dc.description.citedreference | Csiki I, 2005, CLIN CANCER RES, V11, P6634, DOI 10.1158/1078-0432.CCR-05-0436 | - |
dc.description.citedreference | Antman EM, 2005, CIRCULATION, V112, P759, DOI 10.1161/CIRCULATIONAHA.105.568451 | - |
dc.description.citedreference | Spektor G, 2005, NAT CLIN PRACT CARD, V2, P290, DOI 10.1038/ncpcardio0214 | - |
dc.description.citedreference | Gasparini G, 2005, CANCER J, V11, P209 | - |
dc.description.citedreference | Nugent FW, 2005, LUNG CANCER-J IASLC, V48, P267, DOI 10.1016/j.lungcan.2004.11.004 | - |
dc.description.citedreference | Steffel J, 2005, CIRCULATION, V111, P1685, DOI 10.1161/01.CIR.0000160358.63804.C9 | - |
dc.description.citedreference | Lee BL, 2005, CLIN CANCER RES, V11, P2518 | - |
dc.description.citedreference | Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493 | - |
dc.description.citedreference | Sowers JR, 2005, ARCH INTERN MED, V165, P161 | - |
dc.description.citedreference | Reardon DA, 2005, CANCER, V103, P329, DOI 10.1002/cncr.20776 | - |
dc.description.citedreference | Walter MF, 2004, ATHEROSCLEROSIS, V177, P235, DOI 10.1016/atherosclerosis.2004.10.001 | - |
dc.description.citedreference | Osaki M, 2004, APOPTOSIS, V9, P667 | - |
dc.description.citedreference | Zhu L, 2004, CLIN CANCER RES, V10, P4639 | - |
dc.description.citedreference | Wu T, 2004, MOL CANCER THER, V3, P299 | - |
dc.description.citedreference | Hu PJ, 2004, GUT, V53, P195 | - |
dc.description.citedreference | LIPTON A, 2004, ONCOLOGY, V18, P43 | - |
dc.description.citedreference | Wang WH, 2003, J NATL CANCER I, V95, P1784, DOI 10.1093/jnci/djg106 | - |
dc.description.citedreference | Nam SY, 2003, APMIS, V111, P1105 | - |
dc.description.citedreference | Leng J, 2003, HEPATOLOGY, V38, P756, DOI 10.1053/jhep.2003.50380 | - |
dc.description.citedreference | Chenevard R, 2003, CIRCULATION, V107, P405, DOI 10.1161/01.CIR.0000051361.69808.3A | - |
dc.description.citedreference | Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200 | - |
dc.description.citedreference | Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/mrc839 | - |
dc.description.citedreference | Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780 | - |
dc.description.citedreference | Waskewich C, 2002, CANCER RES, V62, P2029 | - |
dc.description.citedreference | Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje | - |
dc.description.citedreference | Lauder A, 2001, MOL CELL BIOL, V21, P5797 | - |
dc.description.citedreference | Lawlor MA, 2001, J CELL SCI, V114, P2903 | - |
dc.description.citedreference | Akre K, 2001, BRIT J CANCER, V84, P965 | - |
dc.description.citedreference | Yamaguchi A, 2001, J BIOL CHEM, V276, P5256 | - |
dc.description.citedreference | Leung WK, 2001, BRIT J CANCER, V84, P335 | - |
dc.description.citedreference | Bombardier C, 2000, NEW ENGL J MED, V343, P1520 | - |
dc.description.citedreference | Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247 | - |
dc.description.citedreference | Sung JJY, 2000, AM J PATHOL, V157, P729 | - |
dc.description.citedreference | Steinbach G, 2000, NEW ENGL J MED, V342, P1946 | - |
dc.description.citedreference | Langman MJS, 2000, BRIT MED J, V320, P1642 | - |
dc.description.citedreference | Hsu AL, 2000, J BIOL CHEM, V275, P11397 | - |
dc.description.citedreference | BOMBARDIER C, 2000, NEW ENGL J MED, V343, P1528 | - |
dc.description.citedreference | Williams CS, 1999, ONCOGENE, V18, P7908 | - |
dc.description.citedreference | Datta SR, 1999, GENE DEV, V13, P2905 | - |
dc.description.citedreference | Ozes ON, 1999, NATURE, V401, P82 | - |
dc.description.citedreference | Kane LP, 1999, CURR BIOL, V9, P601 | - |
dc.description.citedreference | Brunet A, 1999, CELL, V96, P857 | - |
dc.description.citedreference | BARKETT M, 1999, ONCOGENE, V18, P6919 | - |
dc.description.citedreference | Cardone MH, 1998, SCIENCE, V282, P1318 | - |
dc.description.citedreference | Datta SR, 1997, CELL, V91, P231 | - |
dc.description.citedreference | Elder DJE, 1997, CLIN CANCER RES, V3, P1679 | - |
dc.description.citedreference | Williams CS, 1997, J CLIN INVEST, V100, P1325 | - |
dc.description.citedreference | Levy GN, 1997, FASEB J, V11, P234 | - |
dc.description.citedreference | Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237 | - |
dc.description.citedreference | Charalambous D, 1996, J GASTROEN HEPATOL, V11, P307 | - |
dc.description.citedreference | Harris RE, 1996, EPIDEMIOLOGY, V7, P203 | - |
dc.description.citedreference | Pairet M, 1996, FUNDAM CLIN PHARM, V10, P1 | - |
dc.description.citedreference | CROSS DAE, 1995, NATURE, V378, P785 | - |
dc.description.citedreference | FUNKHOUSER EM, 1995, CANCER, V76, P1116 | - |
dc.description.citedreference | THUN MJ, 1993, CANCER RES, V53, P1322 | - |
dc.description.tc | 6 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.